Scilex Holding (SCLXW) Other Working Capital Changes (2021 - 2026)
Scilex Holding (SCLXW) recorded quarterly Other Working Capital Changes of $1.6 million in Q1 2026, down 76.3% quarter-over-quarter from $6.8 million in Q4 2025, and up 1351.16% on a YoY basis from $111221.2 in Q1 2025.
Scilex Holding (SCLXW) Other Working Capital Changes (2021 - 2026) Analysis & Trends
Scilex Holding's Other Working Capital Changes history runs 6 years deep, the most recent figure standing at $1.6 million for Q1 2026.
- In Q1 2026, Other Working Capital Changes rose 1351.16% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $1.7 million (up 241.9% YoY), while the FY2025 annual figure was -$13000.0, down 101.97% from the prior year.
- Other Working Capital Changes was $1.6 million for Q1 2026 at Scilex Holding, down from $6.8 million in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $6.8 million in Q4 2025 to a low of -$6.9 million in Q3 2025.
- Historically, Other Working Capital Changes has averaged $309250.0 across 5 years, with a median of $116500.0 in 2024.
- Biggest YoY gain for Other Working Capital Changes was 2431.6% in 2025; the steepest drop was 2135.4% in 2025.
- A 5-year view of Other Working Capital Changes shows it stood at -$849000.0 in 2022, then climbed by 20.61% to -$674000.0 in 2023, then surged by 139.91% to $269000.0 in 2024, then soared by 2431.6% to $6.8 million in 2025, then slumped by 76.3% to $1.6 million in 2026.
- The last three Other Working Capital Changes figures came in at $1.6 million (Q1 2026), $6.8 million (Q4 2025), and -$6.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Scilex Holding | - | - | 4.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.61 Mn |
| Mar 31, 2026 | 1.61 Mn |
| Dec 31, 2025 | 6.81 Mn |
| Dec 31, 2025 | 6.81 Mn |
| Sep 30, 2025 | -6.90 Mn |
| Sep 30, 2025 | -6.90 Mn |
| Jun 30, 2025 | 206,000.00 |
| Jun 30, 2025 | 206,000.00 |
| Mar 31, 2025 | -129,000.00 |
| Mar 31, 2025 | -129,000.00 |
| Dec 31, 2024 | 269,000.00 |
| Dec 31, 2024 | 269,000.00 |
| Sep 30, 2024 | 339,000.00 |
| Sep 30, 2024 | 339,000.00 |
| Jun 30, 2024 | 27,000.00 |
| Jun 30, 2024 | 27,000.00 |
| Mar 31, 2024 | 26,000.00 |
| Mar 31, 2024 | 26,000.00 |
| Dec 31, 2023 | -674,000.00 |
| Dec 31, 2023 | -674,000.00 |